IPHA

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Retrieved on: 
Tuesday, April 9, 2024
Communications, Health, General Health, Pharmaceutical, Public Relations, Investor Relations, Biotechnology, Euronext Paris, IPHA, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Euronext Paris, Document, IPHA, IPH, Annual report

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2023 Universal Registration Document (Document d’enregistrement universel) for the year ending December 31, 2023 with the French market authority “Autorité des Marchés Financiers” (“AMF”) on April 4, 2024.
  • It can be downloaded (in French) on the Company’s website and on the AMF’s website .
  • The Company also announced today the filing of its annual report on Form 20-F for the year ending December 31, 2023 with the United States Securities and Exchange Commission (“SEC”).
  • It can be also be accessed on the Company’s website and on the SEC’s website .

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Retrieved on: 
Tuesday, March 19, 2024
Professional Services, Health, Finance, Research, Science, Pharmaceutical, Biotechnology, Euronext Paris, IPHA, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below.
  • Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations.

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Euronext Paris, Telephone, Webcast, IPHA, IPH, EDT

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, March 21, 2024 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2023.
  • Participants during the call will be:
    The live webcast will be available at the following link:
    Participants may also join via telephone using the following registration link: https://registrations.events/direct/Q4I409542
    This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com .
  • A replay of the webcast will be available on the Company website for 90 days following the event.

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma

Retrieved on: 
Wednesday, March 6, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CD20, IPH, CD16, NHL, NCR1, Relapse, IPHA, Safety, Therapy, Patient, NK, Euronext Paris, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the first patient was dosed in its Phase 1/2 multicenter trial ( NCT06088654 ), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma (NHL).
  • The study is planned to enroll up to 184 patients.
  • “We are pleased to announce the dosing of a first patient in this Phase 1/2 study evaluating IPH6501, our proprietary ANKET® asset and the first tetraspecific NK Cell Engager to enter the clinic.” commented Dr Sonia Quaratino, Chief Medical Officer at Innate Pharma.
  • In this context, IPH6501 represents an innovative option for the treatment of patients with R/R B-cell non-Hodgkin’s lymphomas and has the potential to fulfil a large unmet need.”

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Euronext Paris, IPH, Neoplasm, Engineering, Doctor of Philosophy, AACR, IPHA, DVM, ADC

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding its preclinical asset IPH45, a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California.
  • "We are excited to present our findings on IPH45 at this year's AACR.
  • Our studies demonstrate that IPH45 effectively inhibits tumor growth both in vitro and in vivo, and it exhibits a favorable safety profile in preclinical studies," stated Prof. Eric Vivier, DVM, PhD, Chief Scientific Officer at Innate Pharma.
  • "These promising results underscore the potential of IPH45 and reflect our dedication to pioneering the next wave of cancer treatments through advanced antibody engineering.

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, IPHA, Euronext Paris, IPH

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

Key Points: 

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in the upcoming investor conference, detailed below.

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Food, HLH, Hemophagocytic lymphohistiocytosis, Euronext Paris, IND, Disease, IPH, Death, IPHA, Pharmaceutical industry

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the lacutamab IND.
  • On October 5, Innate announced that the lacutamab IND has been placed on partial clinical hold by FDA following a recent patient death in the TELLOMAK study.
  • The FDA decision to lift the partial clinical hold is based on the FDA review of the fatal case which Innate, together with a steering committee of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.
  • “We have worked closely with the FDA to diligently resolve the partial clinical hold on the lacutamab IND, which included an in-depth analysis of the fatal case which was due to progression of an aggressive form of the disease,” said Dr Quaratino, Chief Medical Officer of Innate Pharma.

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Marketing, Euronext Paris, Upjohn, Executive, Business administration, IPH, Western Michigan University, University, Central Michigan University, Business development, Supervisory board, EVP, IPHA, Management

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it has strengthened the Company’s leadership and corporate governance with the appointment of two new Executive Board members.
  • Dr. Sonia Quaratino, current EVP, Chief Medical Officer is appointed to the Executive Board.
  • Arvind Sood joins the Company in a newly created position of Executive Vice President, Innate Pharma SA and President of US Operations.
  • “We are taking steps to position Innate Pharma for future success by significantly strengthening our Executive Board now comprising Yannis, Sonia and Arvind,” said Hervé Brailly, interim Chief Executive Officer.

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

Retrieved on: 
Tuesday, December 19, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Health Technology, Clinical Trials, Partnership, Euronext Paris, Doctor of Philosophy, IPH, DVM, Cancer, Patient, SNY, IPHA, Exercise, Senior, Vaccine

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022 .

Key Points: 
  • Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced today that Sanofi has exercised its option to license a natural killer (NK) cell engager program in solid tumors from Innate’s ANKET® (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022 .
  • Following a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization.
  • Innate Pharma is eligible for up to €1.35bn total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.
  • Valeria Fantin, Ph.D., Global Head of Oncology Research at Sanofi, states: “Sanofi is pleased with our collaboration with Innate and continues to be excited at the potential of investigational NK Cell Engagers.